YAP phosphorylation and activation of the sphingolipid metabolic enzyme SGPP2 jointly mediate tumor metabolic adaptation (51); whilst the sphingolipid metabolic enzyme CERK promotes drug resistance in ER+ BC (52–54). Here, SGPP2 is linked to breast cancer.